1. |
[11]Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or High-Dose Dexa methasone for Relapsed Multiple Myeloma[J].N Engl J Med,2005,352:2487-98.
|
2. |
[12]Richardson PG,Chanan-Khan A,Schlossman R,et al.A multicenter phase Ⅱ trial of bortezomib in Patients with previously untreated multiple myeloma:efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy[J].Blood,2005,106:2548.
|
3. |
[13]Wang LM,Weber DM,Delasalle KB,et al.VTD (Velcade,Thelidomide,Dexamethaso me) as primary therapy for newly-diagnosed multiple myeloma[J].Blood,2004,104:210.
|
4. |
[14]Harousseau JL,Attal M,Leleu X,et al.Bortezomib(Velcade)plus decamethas one as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Blood,2004,104:1490.
|
5. |
[15]Peles S,Fisher NM,Devine SM,et al.Bortezomib(velcade)when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)[J].Blood,2005,106:3237.
|
6. |
[16]Geoffrey LU,Fisher NM,Devine SM,et al.Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma[J].Blood,2005,106:2926.
|
7. |
Adams J.The proteasome:structure,function,and role in the cell[J].Cancer Treat Rev,2003,29(suppl 1)3-9.
|
8. |
Kyle RA,Rajkumar SV.Drug therapy of multiple myeloma[J].N Engl J Med,2004,351:1860-73.
|
9. |
Voorhees PM,Dees EC,O’Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:6316-25.
|
10. |
Richardson PG,Mitsiades C.Bortezomib:proteasome inhibition as an effective anticancer therapy[J].Annu Rev Med,2006,57:33-47.
|
11. |
O’Connor OA.Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell ly mphoma[J].Clin Lymphoma Myeloma,2005,6(3):191-9.
|
12. |
Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyelomaactivity of proteasome inhibitor PS-341[J].Blood,2003,101:1530.
|
13. |
Roccaro AM,Hideshima T,Raje N,et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood,2004,104:4903.
|
14. |
Heider U,Kaiser M,Muller C,et al.Treatment of bortezomib increases osteoblast function in patients with multiple myeloma[J].Blood,2005,106:3457.
|
15. |
Richardson PG,Barlogie B,Berenson J,et al.A phase 2study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348:2609-17.
|
16. |
Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progressionin patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-23.
|